Clinical Trials Browser

Phase 2/3 × Stomach Neoplasms × sintilimab × Clear all

NCT06977061 2025-05-16

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

Phase 2/3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05002686 2021-08-24

Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

Phase 2/3 Unknown

Gastrointestinal

Stomach Neoplasms